There are 327 resources available
Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Presenter: Rebecca Dent
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
Presenter: Jean-Pierre Ayoub
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)
Presenter: Antonio Di Meglio
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial
Presenter: Cristina Saura Manich
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
Presenter: Joyce O'Shaughnessy
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis
Presenter: Tomas Pascual
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
Presenter: Nour Abuhadra
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
Presenter: William Jacot
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
The risk of late breast cancer recurrence in Denmark during 17 years of follow-up
Presenter: Rikke Pedersen
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE
Presenter: Sibylle Loibl
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.